TY - JOUR
T1 - CD46: The 'multitasker' of complement proteins
AU - Yamamoto, Hidekazu
AU - Fara, Antonella Francesca
AU - Dasgupta, Prokar
AU - Kemper, Claudia
N1 - Funding Information:
Work in the Kemper laboratory is supported by the MRC Research Grant G1002165 (CK), and the EU-funded Innovative Medicines Initiative BTCURE (CK) . The Dasgupta group is funded by grants from PCUK , The Heathside Trust , EU-FP7 , TUF , GSTT Charity and TSB . The research was also funded by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas’ NHS Foundation Trust and King's College London . The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. The authors acknowledge the support of the MRC Centre for Transplantation.
PY - 2013
Y1 - 2013
N2 - Complement is undeniably quintessential for innate immunity by detecting and eliminating infectious microorganisms. Recent work, however, highlights an equally profound impact of complement on the induction and regulation of a wide range of immune cells. In particular, the complement regulator CD46 emerges as a key sensor of immune activation and a vital modulator of adaptive immunity. In this review, we summarize the current knowledge of CD46-mediated signalling events and their functional consequences on immune-competent cells with a specific focus on those in CD4+ T cells. We will also discuss the promises and challenges that potential therapeutic modulation of CD46 may hold and pose.
AB - Complement is undeniably quintessential for innate immunity by detecting and eliminating infectious microorganisms. Recent work, however, highlights an equally profound impact of complement on the induction and regulation of a wide range of immune cells. In particular, the complement regulator CD46 emerges as a key sensor of immune activation and a vital modulator of adaptive immunity. In this review, we summarize the current knowledge of CD46-mediated signalling events and their functional consequences on immune-competent cells with a specific focus on those in CD4+ T cells. We will also discuss the promises and challenges that potential therapeutic modulation of CD46 may hold and pose.
UR - http://www.scopus.com/inward/record.url?scp=84886734479&partnerID=8YFLogxK
U2 - 10.1016/j.biocel.2013.09.016
DO - 10.1016/j.biocel.2013.09.016
M3 - Short survey
C2 - 24120647
AN - SCOPUS:84886734479
SN - 1357-2725
VL - 45
SP - 2808
EP - 2820
JO - International Journal of Biochemistry and Cell Biology
JF - International Journal of Biochemistry and Cell Biology
IS - 12
ER -
